Citius Oncology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CTOR Nasdaq 2834 citiusonc.com/overview/default.aspx

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Citius Oncology, Inc.

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - Sep 3rd, 2026 6:30 am
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Aug 17th, 2026 6:28 am
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Aug 14th, 2026 2:30 pm
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Aug 14th, 2026 2:30 pm
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Aug 12th, 2026 6:00 am
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - Aug 5th, 2026 7:17 am
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Jul 21st, 2026 7:17 am
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - Jun 1st, 2026 5:00 am
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - May 24th, 2026 5:49 am
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - May 15th, 2026 2:30 pm
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - May 15th, 2026 2:30 pm
Citius raises $36.5m for Lymphir commercialisation - May 6th, 2026 7:04 am
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization - May 5th, 2026 6:00 pm
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - Apr 29th, 2026 6:00 am
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - Apr 15th, 2026 4:35 am
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - Mar 31st, 2026 7:11 am
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - Mar 24th, 2026 6:00 am
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Mar 6th, 2026 1:00 pm